neuroimaging for psychiatrists
TRANSCRIPT
Matt Wall, April, 2021
Neuroimaging for PsychiatristsO r …Eve r y t h i n g yo u a l ways wa nte d to k n o w a b o u t b ra i n p i c t u re s b u t we re a f ra i d to a s k
2www.invicro.com
About me
• Head of MRI applications at Invicro, London, UK• Honorary senior lecturer at Imperial College London• Honorary researcher at University College London
• Current research: Sex hormones, cannabinoids, psychedelics, methods development, reliability/reproducibility
• Likes: Big magnets, guitars, neuropsychopharmacology, Rogue One, cats.
• Dislikes: Brexit, Boris Johnson, The Rise of Skywalker, dogs.
3www.invicro.com
Neuroimaging
4www.invicro.com
Neuroimaging Technologies
• Electroencephalography (EEG)
• Computed Tomography (CT)
• Single Photon Emission Computed Tomograpy (SPECT)
• Positron Emission Tomography (PET)
• Magnetic Resonance Imaging (MRI)
• Magnetoencephalography (MEG)
5www.invicro.com
Current Neuroscience Technologies
Provide large-scale systems-level information
PET and MRI provide complementary information
6www.invicro.com
PET
• Provides precise, quantitative information about a particular compound/receptor.
• Invasive, and exposes the patient to radiation.
• Temporal and spatial resolution fairly poor.
• Sensitivity extremely high
7www.invicro.com
PET
Cyclotron Chemistry Patient Data
8www.invicro.com
PET scanners
• Thousands of detectors arranged around patient• Count many 100 millions of coincidences to determine radiotracer distribution• Scan for 60-120 minutes• Measure dynamic data
9www.invicro.com
FDG PET
• Uses [18F]Flourodeoxyglucose as a radiotracer• Routine use in oncology• Radiation accumulates in the most metabolically active tissues
10www.invicro.com
FDG PET in the brain
• Brain is very metabolically active (5% body weight, 20% oxygen consumption)
• Useful in differentiating dementia subtypes
11www.invicro.com
PET in drug development
Imaging the Drug“Biodistribution”
Imaging the Target“Occupancy”
Measures brain uptake of the radiolabelleddrug candidate
Measures the change in target availability post drug administration
Provides a measure of “free” drug concentration (VF)
Provides direct measure of target occupancy by the drug (∆VS)
Requires radiolabelling of the drug candidate with a positron emitting nucleide - often feasible
Requires a usable radioligand;more difficult than labelling a drug
12www.invicro.com
Biodistribution studies
Some species variability in CNS penetration
Rat Pig Human
Human evaluation of drug candidates:
[11C]Compound A [11C]Compound B
13www.invicro.com
Occupancy studies
Ligand Target
[11C]Carfentanil µ-Opioid
[18F]FDOPA Dopamine Synthesis
[11C]PHNO D2/D3 receptors
[11C]CIMBI-36 5HT2A receptor
[11C]UCB-J Synaptic vesicle 2 (SV2A; synaptic density)
[11C]PBR28 Translocator Protein (TSPO)
[18F]Flutemetamol ß-amyloid
[18F]T808 Tau
• Requires a suitable PET ligand (radiotracer compound):• Penetrates the BBB• Specific pharmacology• Right PK profile• Easy synthesis (ideally)
14www.invicro.com
Occupancy studies
Baseline
Plasma Conc
Occ
upan
cy
BA
RadioligandDrugTarget
BA
Post-drug
Occupancy is dose and time dependent
15www.invicro.com
MRI
• Huge, super-conducting magnet:
• 3Tesla = 30,000 Gauss (Earth magnetic field = 0.5 Gauss)
• Completely safe, if no (ferrous) metal around.
• Very flexible imaging method – multiple types of data from same patient
• Signal-to-noise-ratio (SNR) generally lower than PET
16www.invicro.com
MRI Physics
Signal (RF ‘echo’)Protons align RF pulse applied
Gradient fields
17www.invicro.com
Anatomical MRI
Provides structural information
• Many different versions available, which provide different ‘contrast’ and highlight different tissue types
18www.invicro.com
Functional MRI
• Adapts MRI to register the magnetic properties of oxygenated/deoxygenated hemoglobin, allowing imaging of real-time blood flow
• Relies on the BOLD (Blood Oxygen Level Dependent) effect
• Pros:– Can image whole brain simultaneously– Very flexible in terms of stimulus presentation– Decent spatial and temporal resolution– Can examine brain connectivity with resting-state fMRI
• Cons:– Blood flow is only an indirect correlate of brain activity– Interpretation of results can sometimes be difficult
19www.invicro.com
Bonding
Neutral
Bonding - Neutral
Task-fMRI
• Very flexible: • Audio • Video• Olfactory • Pain • Multiple response types
• Many different experimental designs possible
• Relies on ‘method of subtraction’ to isolate effects.
20www.invicro.com
Resting-state fMRI
• Brain is metabolically very active, even at rest• Spontaneous fluctuations are coherent, and
organized into spatially discrete networks:• Default-mode/task-negative• Executive/task-positive• Visual• Auditory• Language• Attention• Somatomotor
• Can be a sensitive measure of:• Development/Aging• Pathology• Acute drug effects
21www.invicro.com
Pharmacological RS-fMRI
• Effects of different types of cannabis on resting-state networks
MB Wall et al., Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity. J. Psychopharmacol. 33, 822–830 (2019).
22www.invicro.com
Drug response pathway
Tissue response
Drug in Blood
2nd MessengerResponse
Physiological/Behavioural Response
Clinical outcome
Drug in tissue
Drug at Target
23www.invicro.com
Drug response pathway
Clinical outcomeDrug in Blood
Drug in tissue
Drug at Target
2nd MessengerResponse
Tissue response
Physiological/Behavioural Response
24www.invicro.com
Drug response pathway
Clinical outcomeDrug in Blood
Drug in tissue
Drug at Target
2nd MessengerResponse
Tissue response
Physiological/Behavioural Response
25www.invicro.com
Drug response pathway
Clinical outcomeDrug in Blood
Drug in tissue
Drug at Target
2nd MessengerResponse
Tissue response
Physiological/Behavioural Response
PET (f)MRI
26www.invicro.com
What can neuroimaging do for psychiatry?
• Progress in neuroimaging has been extraordinary:
1973 2015
• Clinical treatments/outcomes in psychiatry have not progressed to the same extent
27www.invicro.com
Prof. Tom InselDirector of NiMH
(2002-2015)
“I spent 13 years at NIMH really pushing on the neuroscience and genetics of mental disorders, and when I look back on that I realize that while I think I succeeded at getting lots of really cool papers published by cool scientists at fairly large costs—I think $20 billion—I don’t think we moved the needle in reducing suicide, reducing hospitalizations, improving recovery for the tens of millions of people who have mental illness.”
28www.invicro.com
Mapping symptoms to brain featuresProblem 1: Clinical heterogeneity• Patient 1: Sleepiness/fatigue, loss of appetite, low mood, feelings of worthlessness• Patient 2: Insomnia, weight gain, anhedonia, anxiety, suicidal ideation
Same underlying dysfunction?
Problem 2: One symptom, multiple causes• Fatigue:
• Major depression• Post-viral• Stress• Endocrine problem (hypothyroidism, diabetes)• Sleep issues• Etc., etc.
Roiser, J (2015) What has neuroscience ever done for us? The Psychologist 28, 284-287. https://thepsychologist.bps.org.uk/volume-28/april-2015/what-has-neuroscience-ever-done-us
29www.invicro.com
Overlapping distributions
Hypothetical study:• Group 1: N=100 Major depression patients• Group 2: N=100 Healthy matched controls• Result: 10% less brain activity (on average) in the hippocampus of depressed subjects
Depressed ControlsPatient X
Brain imaging not useful for diagnosis.(Perhaps never will be?)
Problem is moving from statistical effects (in groups) to reliable biomarkers (in individuals)
30www.invicro.com
Schizophrenia and neuroimaging
Shepherd, et al. (2012). Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neuroscience & Biobehavioral Reviews, 36(4), 1342-1356.
Giraldo-Chica, M., & Woodward, N. D. (2017). Review of thalamocortical resting-state fMRI studies in schizophrenia. Schizophrenia research, 180, 58-63.
Decreased gray matter
31www.invicro.com
Mapping prodromal psychosis
P. Fusar-Poli, P. McGuire, S. Borgwardt, Mapping prodromal psychosis: A critical review of neuroimaging studies. Eur. Psychiatry. 27, 181–191 (2012).
High riskControls
Decreased gray matterPET-fMRI integration
32www.invicro.com
PET and antipsychotics
• Patients with extrapyramidal syndromes (EPS) have higher D2 receptor occupancy (above 80%) than patients with a good clinical response but no EPS (65–80%).
Nord, M., & Farde, L. (2011). Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS neuroscience & therapeutics, 17(2), 97-103.
• Clozapine has therapeutic effects at lower levels of D2 occupancy
• Fewer EPS effects• More complex
pharmacology (higher affinity for D4R)
33www.invicro.com
Depression and neuroimaging
• Strong focus on the structure and function of the subgenual cingulate
Drevets, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 386 (1997), pp. 824–827.
FDG-PET
Greicius, et al. Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus. Biol. Psychiatry. 62, 429–437 (2007).
RS-fMRI
34www.invicro.com
Depression and deep brain stimulation• Electrodes implanted in the sgACC in treatment-resistant depression
Merkl et al. Antidepressant effects after short-term and chronic stimulation of the subgenual cingulate gyrus in treatment-resistant depression. Exp. Neurol. 249, 160–168 (2013).
Meta-analysis conclusion:“DBS applied to the SCC seems to be associated with relatively large response and remission rates in the short-and medium- to long-term in patients with severe TRD. ”
But:• Only open-label studies• Very high cost• Very invasive• Does not work for many patients
Berlim et al. Effectiveness and acceptability of deep brain stimulation (DBS) of the subgenual cingulate cortex for treatment-resistant depression: A systematic review and exploratory meta-analysis. J. Affect. Disord. 159, 31–38 (2014).
35www.invicro.com
Depression and psychedelics
• Recent ‘psychedelic renaissance’; research re-started after ~50 years of neglect
R. L. Carhart-Harris, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry. 3, 619–627 (2016).
RS-fMRI
R. L. Carhart-Harris, L. Roseman, M. Bolstridge, L. Demetriou, J. N. Pannekoek, M. B. Wall, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci. Rep. 7, 13187 (2017).
36www.invicro.com
Depression and psychedelics
• First head-to-head comparison clinical trial of psilocybin vs. SSRI (escitalopram)
Carhart-Harris et al. Trial of Psilocybin versus Escitalopram for Depression. N. Engl. J. Med. (2021), doi:10.1056/NEJMoa2032994.
B
Psilo > Esc
37www.invicro.com
Wrap-up
• Neuroimaging is good basic science, but translational results have been limited
• Translation to the clinic still a topic of strong interest, and much effort
• Big role to play in novel drug development
• ‘Big data’ and machine (deep) learning hold some promise
• Other approaches (TMS, neurofeedback) may also have potential
38www.invicro.com
Question time!
39www.invicro.com
40www.invicro.com
Spare/cut slides follow…
41www.invicro.com
Canonical Analysis Pipeline
Data Conversion
Slice-timeCorrection
Pre-Processing
ThresholdingVisualisation
Analysis
Motion Correction
Spatial Normalisation
Spatial Smoothing
Temporal Filtering
Modelling
Model-free analysis
Contrasts
OptionalNecessary
42www.invicro.com
43www.invicro.com
Visualisation
44www.invicro.com
Task-fMRI: Kisspeptin
FSHLH
KISSPEPTIN
Testosterone/Oestrogen
Hypothalamus
Pituitary
Gonads
BBB
Kisspeptin > Placebo
A. N. Comninos, M. B. Wall, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J. Clin. Invest. 127, 709–719 (2017).
45www.invicro.com
Multifactorial causation… yes… but no.
Mental IllnessGenetics
46www.invicro.com
Further resourcesHandbook of functional MRI data analysis: Poldrack, Mumford, Nichols (2011)
“What we can and cannot do with fMRI” Logothetis (2008). https://www.nature.com/articles/nature06976
”A hitchhiker’s guide to functional magnetic resonance imaging” Soares et al. (2016).https://www.frontiersin.org/articles/10.3389/fnins.2016.00515/full
Oxford neuroimaging primers: